@article{HungKasperkowitzKurzetal.2023,
  author    = {Hung, Sophia and Kasperkowitz, Amelie and Kurz, Florian and Dreher, Liane and Diessner, Joachim and Ibrahim, Eslam S. and Schwarz, Stefan and Ohlsen, Knut and Hertlein, Tobias},
  title     = {Next-generation humanized NSG-SGM3 mice are highly susceptible to Staphylococcus aureus infection},
  series = {Frontiers in Immunology},
  volume    = {14},
  journal   = {Frontiers in Immunology},
  doi       = {10.3389/fimmu.2023.1127709},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-306966},
  year      = {2023},
  abstract  = {Humanized hemato-lymphoid system mice, or humanized mice, emerged in recent years as a promising model to study the course of infection of human-adapted or human-specific pathogens. Though Staphylococcus aureus infects and colonizes a variety of species, it has nonetheless become one of the most successful human pathogens of our time with a wide armory of human-adapted virulence factors. Humanized mice showed increased vulnerability to S. aureus compared to wild type mice in a variety of clinically relevant disease models. Most of these studies employed humanized NSG (NOD-scid IL2Rgnull) mice which are widely used in the scientific community, but show poor human myeloid cell reconstitution. Since this immune cell compartment plays a decisive role in the defense of the human immune system against S. aureus, we asked whether next-generation humanized mice, like NSG-SGM3 (NOD-scid IL2Rgnull-3/GM/SF) with improved myeloid reconstitution, would prove to be more resistant to infection. To our surprise, we found the contrary when we infected humanized NSG-SGM3 (huSGM3) mice with S. aureus: although they had stronger human immune cell engraftment than humanized NSG mice, particularly in the myeloid compartment, they displayed even more pronounced vulnerability to S. aureus infection. HuSGM3 mice had overall higher numbers of human T cells, B cells, neutrophils and monocytes in the blood and the spleen. This was accompanied by elevated levels of pro-inflammatory human cytokines in the blood of huSGM3 mice. We further identified that the impaired survival of huSGM3 mice was not linked to higher bacterial burden nor to differences in the murine immune cell repertoire. Conversely, we could demonstrate a correlation of the rate of humanization and the severity of infection. Collectively, this study suggests a detrimental effect of the human immune system in humanized mice upon encounter with S. aureus which might help to guide future therapy approaches and analysis of virulence mechanisms.},
  language  = {en}
}
@article{LeonhardtWinklerKollikowskietal.2023,
  author    = {Leonhardt, Jonas and Winkler, Marcela and Kollikowski, Anne and Schiffmann, Lisa and Quenzer, Anne and Einsele, Hermann and L{\"o}ffler, Claudia},
  title     = {Mind-body-medicine in oncology—from patient needs to tailored programs and interventions},
  series = {Frontiers in Psychology},
  volume    = {14},
  journal   = {Frontiers in Psychology},
  issn      = {1664-1078},
  doi       = {10.3389/fpsyg.2023.1140693},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-321970},
  year      = {2023},
  abstract  = {Introduction: National and international guidelines recommend early integration of evidence-based multimodal interventions and programs, especially with a focus on relaxation techniques and other Mind-Body-based methods to maintain the quality of life of oncology patients, improve treatment tolerability, and promote healthy lifestyle behaviors. Consequently, we aim to understand what drives patients and how they navigate integrative medicine to best advise them. This study aimed to detect possible topics of particular interest to patients and identify the patient groups that could benefit most from further programs. Furthermore, we aimed to investigate if patients are open-minded toward integrative oncology concepts and learn about their motivational level to maintain or change behavior. Methods: Between August 2019 and October 2020 we surveyed patients undergoing oncological therapy in a university oncological outpatient center using a custom-developed questionnaire based on established Mind-Body Medicine concepts. Results: We included 294 patients with various cancers. More than half reported problems sleeping through (61\%) and 42\% felt stressed frequently, invariably rating this as detrimental to their health. Moreover, a slight majority (52\%) felt physically limited due to their disease and only 30\% performed defined exercise programs. Women were significantly more likely to feel stressed and reported with alarming frequency that they often feel "everything was up to them." The 40-65-year-olds reported significantly less restful sleep, more stress and were more dissatisfied with their situation. However, this group already used natural remedies most frequently and was most often motivated to use relaxation techniques in the next 6 months. The lower the perceived individual energy level (EL), the less frequently patients did sport, the more frequently they felt their disease impaired their activity, mostly feeling stressed and tense. We also found significant associations between negative emotions/thoughts and the variables "sleep," "use of relaxation techniques," "personal stress perception," and "successful lifestyle modification." Conclusion: Mind-Body programs that focus on patient's individual resources, with tools to explore impairing patterns of self-perception and cognitive biases, can be a valuable resource for oncology patients and should therefore be part of an integrative medical treatment concept.},
  language  = {en}
}
@article{HaakeHaackSchaeferetal.2023,
  author    = {Haake, Markus and Haack, Beatrice and Sch{\"a}fer, Tina and Harter, Patrick N. and Mattavelli, Greta and Eiring, Patrick and Vashist, Neha and Wedekink, Florian and Genssler, Sabrina and Fischer, Birgitt and Dahlhoff, Julia and Mokhtari, Fatemeh and Kuzkina, Anastasia and Welters, Marij J. P. and Benz, Tamara M. and Sorger, Lena and Thiemann, Vincent and Almanzar, Giovanni and Selle, Martina and Thein, Klara and Sp{\"a}th, Jacob and Gonzalez, Maria Cecilia and Reitinger, Carmen and Ipsen-Escobedo, Andrea and Wistuba-Hamprecht, Kilian and Eichler, Kristin and Filipski, Katharina and Zeiner, Pia S. and Beschorner, Rudi and Goedemans, Renske and Gogolla, Falk Hagen and Hackl, Hubert and Rooswinkel, Rogier W. and Thiem, Alexander and Romer Roche, Paula and Joshi, Hemant and P{\"u}hringer, Dirk and W{\"o}ckel, Achim and Diessner, Joachim E. and R{\"u}diger, Manfred and Leo, Eugen and Cheng, Phil F. and Levesque, Mitchell P. and Goebeler, Matthias and Sauer, Markus and Nimmerjahn, Falk and Schuberth-Wagner, Christine and Felten, Stefanie von and Mittelbronn, Michel and Mehling, Matthias and Beilhack, Andreas and van der Burg, Sjoerd H. and Riedel, Angela and Weide, Benjamin and Dummer, Reinhard and Wischhusen, J{\"o}rg},
  title     = {Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment},
  series = {Nature Communications},
  volume    = {14},
  journal   = {Nature Communications},
  doi       = {10.1038/s41467-023-39817-3},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-357333},
  year      = {2023},
  abstract  = {Immune checkpoint blockade therapy is beneficial and even curative for some cancer patients. However, the majority don't respond to immune therapy. Across different tumor types, pre-existing T cell infiltrates predict response to checkpoint-based immunotherapy. Based on in vitro pharmacological studies, mouse models and analyses of human melanoma patients, we show that the cytokine GDF-15 impairs LFA-1/β2-integrin-mediated adhesion of T cells to activated endothelial cells, which is a pre-requisite of T cell extravasation. In melanoma patients, GDF-15 serum levels strongly correlate with failure of PD-1-based immune checkpoint blockade therapy. Neutralization of GDF-15 improves both T cell trafficking and therapy efficiency in murine tumor models. Thus GDF-15, beside its known role in cancer-related anorexia and cachexia, emerges as a regulator of T cell extravasation into the tumor microenvironment, which provides an even stronger rationale for therapeutic anti-GDF-15 antibody development.},
  language  = {en}
}
@article{IpWischhusen2023,
  author    = {Ip, Chi Wang and Wischhusen, J{\"o}rg},
  title     = {Versatile guardians: regenerative regulatory T cells in Parkinson's disease rodent models},
  series = {Signal Transduction and Targeted Therapy},
  volume    = {8},
  journal   = {Signal Transduction and Targeted Therapy},
  doi       = {10.1038/s41392-023-01681-4},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-357674},
  year      = {2023},
  abstract  = {No abstract available.},
  language  = {en}
}
@article{HeidtKaemmererFobkeretal.2023,
  author    = {Heidt, Christina and K{\"a}mmerer, Ulrike and Fobker, Manfred and R{\"u}ffer, Andreas and Marquardt, Thorsten and Reuss-Borst, Monika},
  title     = {Assessment of intestinal permeability and inflammation bio-markers in patients with rheumatoid arthritis},
  series = {Nutrients},
  volume    = {15},
  journal   = {Nutrients},
  number    = {10},
  issn      = {2072-6643},
  doi       = {10.3390/nu15102386},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-319377},
  year      = {2023},
  abstract  = {Increased intestinal permeability and inflammation, both fueled by dysbiosis, appear to contribute to rheumatoid arthritis (RA) pathogenesis. This single-center pilot study aimed to investigate zonulin, a marker of intestinal permeability, and calprotectin, a marker of intestinal inflammation, measured in serum and fecal samples of RA patients using commercially available kits. We also analyzed plasma lipopolysaccharide (LPS) levels, a marker of intestinal permeability and inflammation. Furthermore, univariate, and multivariate regression analyses were carried out to determine whether or not there were associations of zonulin and calprotectin with LPS, BMI, gender, age, RA-specific parameters, fiber intake, and short-chain fatty acids in the gut. Serum zonulin levels were more likely to be abnormal with a longer disease duration and fecal zonulin levels were inversely associated with age. A strong association between fecal and serum calprotectin and between fecal calprotectin and LPS were found in males, but not in females, independent of other biomarkers, suggesting that fecal calprotectin may be a more specific biomarker than serum calprotectin is of intestinal inflammation in RA. Since this was a proof-of-principle study without a healthy control group, further research is needed to validate fecal and serum zonulin as valid biomarkers of RA in comparison with other promising biomarkers.},
  language  = {en}
}
@phdthesis{WegmanngebWallo2024,
  author    = {Wegmann [geb. Wallo], Monika Eva},
  title     = {Tumorkachexie diagnostizieren und behandeln - die Rolle der Bioimpedanzanalyse},
  doi       = {10.25972/OPUS-35150},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-351509},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2024},
  abstract  = {Die tumorbedingte Mangelern{\"a}hrung und Kachexie ist ein Syndrom mit sowohl medizinischer als auch gesundheits{\"o}konomischer Relevanz. In den letzten Jahren wurde ein besseres Verst{\"a}ndnis f{\"u}r die komplexe Pathophysiologie, bestehend aus Stoffwechselst{\"o}rungen, verminderter Energiezufuhr und Entz{\"u}ndungsprozessen, die zum fortschreitenden Muskel- und Fettmassenverlust f{\"u}hren, erreicht. Dieses Verst{\"a}ndnis dient bis heute der Entwicklung m{\"o}glicher pr{\"a}ventiver und therapeutischer Ans{\"a}tze. Geeignete Screening-Tests tragen dazu bei, das Syndrom rechtzeitig zu erkennen und weitere Maßnahmen einzuleiten. Da der Muskel- und Fettmassenverlust nicht immer durch einen reinen Gewichtsverlust gekennzeichnet ist, ist die Erfassung der K{\"o}rperzusammensetzung ein wesentlicher Bestandteil in der Betreuung onkologisch Erkrankter. Die BIA ist ein hierf{\"u}r geeignetes Verfahren, welches leicht in den klinischen Alltag zu integrieren ist und besonders zur interindividuellen Verlaufskontrolle herangezogen werden k{\"o}nnte. Ern{\"a}hrungsmedizinische und bewegungstherapeutische Maßnahmen sind bereits fester Bestandteil internationaler Leitlinien. F{\"u}r pharmakologische Therapiekonzepte besteht noch weiterer Forschungsbedarf, um eine Arzneimittelzulassung zu erreichen. Eine alleinige Intervention ist in der Behandlung der onkologischen Mangelern{\"a}hrung und Kachexie wenig effektiv. Deshalb m{\"u}ssen die Bedeutung und der potentielle Nutzen einer Kombination der einzelnen Behandlungsbausteine n{\"a}her betrachtet werden, um eine bessere Evidenz zu erhalten. Der nachweisliche Mangel an Ern{\"a}hrungsstrukturen und ern{\"a}hrungsmedizinischer Fachkompetenz, Schwierigkeiten der Definitionsentwicklung und Gestaltung von Studien sowie finanzierungstechnische Fragen stellen ein zentrales Problem in der angemessenen Betreuung der Erkrankten dar. Jedoch bestehen klare Handlungsempfehlungen und Strategien, durch die entsprechende Herausforderungen reduziert oder beseitigt werden k{\"o}nnten. Dadurch profitieren sowohl Erkrankte als auch das Gesundheitssystem. Dies kann durch eine verbesserte Versorgung mittels Pr{\"a}vention, fr{\"u}hzeitiger Erfassung, Diagnose und Einleitung angebrachter Therapiemaßnahmen auf dem Gebiet der tumorbedingten Mangelern{\"a}hrung und Kachexie erreicht werden.},
  subject      = {Kachexie},
  language  = {de}
}
@article{ZeinerZinkeKowalewskietal.2018,
  author    = {Zeiner, P. S. and Zinke, J. and Kowalewski, D. J. and Bernatz, S. and Tichy, J. and Ronellenfitsch, M. W. and Thorsen, F. and Berger, A. and Forster, M. T. and Muller, A. and Steinbach, J. P. and Beschorner, R. and Wischhusen, J. and Kvasnicka, H. M. and Plate, K. H. and Stefanović, S. and Weide, B. and Mittelbronn, M. and Harter, P. N.},
  title     = {CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival},
  series = {Acta Neuropathologica Communications},
  volume    = {6},
  journal   = {Acta Neuropathologica Communications},
  doi       = {10.1186/s40478-018-0521-5},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-233882},
  year      = {2018},
  abstract  = {Abstract Despite multidisciplinary local and systemic therapeutic approaches, the prognosis for most patients with brain metastases is still dismal. The role of adaptive and innate anti-tumor response including the Human Leukocyte Antigen (HLA) machinery of antigen presentation is still unclear. We present data on the HLA class II-chaperone molecule CD74 in brain metastases and its impact on the HLA peptidome complexity. We analyzed CD74 and HLA class II expression on tumor cells in a subset of 236 human brain metastases, primary tumors and peripheral metastases of different entities in association with clinical data including overall survival. Additionally, we assessed whole DNA methylome profiles including CD74 promoter methylation and differential methylation in 21 brain metastases. We analyzed the effects of a siRNA mediated CD74 knockdown on HLA-expression and HLA peptidome composition in a brain metastatic melanoma cell line. We observed that CD74 expression on tumor cells is a strong positive prognostic marker in brain metastasis patients and positively associated with tumor-infiltrating T-lymphocytes (TILs). Whole DNA methylome analysis suggested that CD74 tumor cell expression might be regulated epigenetically via CD74 promoter methylation. CD74\(^{high}\) and TIL\(^{high}\) tumors displayed a differential DNA methylation pattern with highest enrichment scores for antigen processing and presentation. Furthermore, CD74 knockdown in vitro lead to a reduction of HLA class II peptidome complexity, while HLA class I peptidome remained unaffected. In summary, our results demonstrate that a functional HLA class II processing machinery in brain metastatic tumor cells, reflected by a high expression of CD74 and a complex tumor cell HLA peptidome, seems to be crucial for better patient prognosis.},
  language  = {en}
}
@phdthesis{Wallner2024,
  author    = {Wallner, Theresa Veronika},
  title     = {Auswirkungen von Endometriose und ihrer vollst{\"a}ndigen Resektion auf die Embryonenqualit{\"a}t},
  doi       = {10.25972/OPUS-35024},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-350246},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2024},
  abstract  = {Ziel dieser Arbeit war es, den Einfluss von Endometriose sowie den Einfluss einer vollst{\"a}ndigen Endometriose-Resektion auf morphokinetische, mit dem Implantationserfolg korrelierende Aspekte der Embryonenqualit{\"a}t zu untersuchen. F{\"u}r die zugrundeliegende retrospektive Studie wurden 258 im Rahmen von IVF- und/oder ICSI-Zyklen befruchtete und kultivierte Embryonen von 44 Patientinnen mit histologisch gesicherter Endometriose und 43 Patientinnen mit laparoskopisch ausgeschlossener Endometriose ausgewertet. Sowohl Endometriose als auch die vollst{\"a}ndige Endometriose-Resektion wurden als Einflussfaktor der fr{\"u}hen Embryonalentwicklung untersucht. Hierf{\"u}r wurde unter Anwendung des KIDScore\(^{TM}\) D3 und D5 Implantationsdaten-Algorithmus die Morphokinetik der jeweiligen Embryonen verglichen. Die Analyse ergab keine signifikanten Unterschiede bei den medianen KIDScores\(^{TM}\) D3 zwischen den drei Gruppen aus Patientinnen ohne Endometriose, Patientinnen mit vollst{\"a}ndig resezierter Endometriose und Patientinnen ohne vollst{\"a}ndige operative Entfernung ihrer Endometriose. Bei den KIDScores\(^{TM}\) D5 erreichten die Embryonen von Patientinnen mit Endometriose ohne vollst{\"a}ndige Resektion einen Medianwert von 2,6 (auf einer Skala von 1 bis 9,9), w{\"a}hrend die Embryonen der Kontrollgruppe aus Patientinnen ohne Endometriose einen Wert von 6,8 erreichten (p = 0,003). Der Medianwert f{\"u}r Embryonen von Endometriose-Patientinnen mit vollst{\"a}ndiger chirurgischer Entfernung ihrer Endometriose betrug 7,2, was einen signifikanten Anstieg im Vergleich zu Embryonen von Patientinnen ohne vollst{\"a}ndige Resektion darstellt (p = 0,002). Die Umrechnung in die Effektst{\"a}rke d (Cohens d) ergab einen mittleren Effekt (d = 0,639) f{\"u}r „keine Endometriose" versus „Endometriose ohne Resektion" sowie einen großen Effekt (d = 0,93) f{\"u}r „Endometriose-Komplettresektion" versus „Endometriose ohne Resektion". In einer Fallserie aus vier Patientinnen, die sich sowohl vor als auch nach vollst{\"a}ndiger Resektion ihrer Endometriose IVF-/ICSI-Zyklen unterzogen hatten, zeigten drei von vier Patientinnen eine deutliche Verbesserung der KIDScores\(^{TM}\) nach vollst{\"a}ndiger Resektion. Die Schwangerschafts- und Abortraten zwischen Frauen mit und ohne Endometriose(resektion) wichen nicht signifikant voneinander ab. Zusammenfassend scheint die vollst{\"a}ndige Resektion der Endometriose die ansonsten tendenziell verminderte Embryonenqualit{\"a}t von Patientinnen, die sich einer k{\"u}nstlichen Befruchtung unterziehen, zu verbessern. Die Daten sprechen daher daf{\"u}r, Patientinnen mit Endometriose vor IVF oder ICSI zu einem chirurgischen Eingriff zu raten.},
  subject      = {Endometriose},
  language  = {de}
}
@phdthesis{Winkler2024,
  author    = {Winkler, Jana},
  title     = {Einfluss von D-β-Hydroxybutyrat auf Stoffwechsel und Interaktion mit Chemo-/Strahlentherapie bei triple negativen Mamma-Karzinom Zellen},
  doi       = {10.25972/OPUS-34704},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-347044},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2024},
  abstract  = {Das triple negative Mamma-Karzinom stellt eine Tumorart dar, welche besonders junge Frauen betrifft und eine schlechte Prognose aufweist. Unterst{\"u}tzende und pro- gnoseverbessernde Therapien sind deshalb Gegenstand aktueller Forschung. Eine m{\"o}gliche unterst{\"u}tzende Therapie stellt hierbei die ketogene Di{\"a}t dar. Diese Arbeit untersuchte die Fragestellung, ob β-Hydroxybutyrat (3OHB), welches als Hauptme- tabolit unter ketogener Di{\"a}t oder beim Fasten erh{\"o}ht ist, Einfluss auf das Zellwachs- tum triple-negativer Brustkrebszellen aus{\"u}bt. Außerdem wurde eruiert, ob 3OHB die {\"u}blichen Behandlungsformen - Chemotherapie und Strahlentherapie - positiv oder negativ beeinflusst. In vitro wurden Versuche mit drei triple-negativen Brust- krebszellreihen unter m{\"o}glichst physiologischen Bedingungen durchgef{\"u}hrt. Hierbei konnte durch 3OHB weder ein wachstumsf{\"o}rdernder noch ein wachstumshemmender Effekt beobachtet werden. Genauso zeigte sich bei den Chemo- oder Strahlenthera- pieversuchen keine durch 3OHB induzierte Wechselwirkung. In vivo durchgef{\"u}hrte Studien {\"u}ber den Einfluss einer ketogenen Di{\"a}t finden sich nur vereinzelt. Um be- lastbare Daten zu erhalten werden deshalb weitere Studien in Zukunft vonn{\"o}ten sein. Eine ketogene Di{\"a}t k{\"o}nnte hierbei im Rahmen eines multimodalen Therapie- konzeptes eine unterst{\"u}tzende Rolle spielen, wof{\"u}r erste Einzelfallstudien Hinweise geben},
  subject      = {Ketogene Kost},
  language  = {de}
}
@article{LoebLinsmeierHerbertetal.2023,
  author    = {L{\"o}b, Sanja and Linsmeier, Eva and Herbert, Saskia-Laureen and Schlaiß, Tanja and Kiesel, Matthias and Wischhusen, J{\"o}rg and Salmen, Jessica and Kranke, Peter and Quenzer, Anne and Kurz, Florian and Weiss, Claire and Gerhard-Hartmann, Elena and W{\"o}ckel, Achim and Diessner, Joachim},
  title     = {Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases},
  series = {Journal of Cancer Research and Clinical Oncology},
  volume    = {149},
  journal   = {Journal of Cancer Research and Clinical Oncology},
  number    = {8},
  doi       = {10.1007/s00432-022-04486-0},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-324068},
  pages     = {5417-5428},
  year      = {2023},
  abstract  = {Purpose Therapeutic options for breast cancer (BC) treatment are constantly evolving. The Human Epidermal Growth Factor 2 (HER2)-low BC entity is a new subgroup, representing about 55\% of all BC patients. New antibody-drug conjugates demonstrated promising results for this BC subgroup. Currently, there is limited information about the conversion of HER2 subtypes between primary tumor and recurrent disease. Methods This retrospective study included women with BC at the University Medical Centre Wuerzburg from 1998 to 2021. Data were retrieved from patients' records. HER2 evolution from primary diagnosis to the first relapse and the development of secondary metastases was investigated. Results In the HR-positive subgroup without HER2 overexpression, HER2-low expression in primary BC was 56.7 vs. 14.6\% in the triple-negative subgroup (p < 0.000). In the cohort of the first relapse, HER2-low represented 64.1\% of HR-positive vs. 48.2\% of the triple-negative cohort (p = 0.03). In patients with secondary metastases, HER2-low was 75.6\% vs. 50\% in the triple negative subgroup (p = 0.10). The subgroup of HER2-positive breast cancer patients numerically increased in the course of disease; the HER2-negative overall cohort decreased. A loss of HER2 expression from primary BC to the first relapse correlated with a better OS (p = 0.018). No clinicopathological or therapeutic features could be identified as potential risk factors for HER2 conversion. Conclusion HER2 expression is rising during the progression of BC disease. In view of upcoming therapeutical options, the re-analysis of newly developed metastasis will become increasingly important.},
  language  = {en}
}